Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 4Gynecologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Leukemia, Myeloid, Chronic-Phase 12Leukemia 6Gastrointestinal Stromal Tumors 6Neoplasm Metastasis 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Melanoma 3Synovitis, Pigmented Villonodular 2Recurrence 2Ovarian Neoplasms 2Hematologic Diseases 2Blast Crisis 2Substance Withdrawal Syndrome 1Peritoneal Neoplasms 1Neoplastic Processes 1Neoplasm, Residual 1Necrosis 1Myeloproliferative Disorders 1Mucosal Lentiginous Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Glioma 1Giant Cell Tumor of Tendon Sheath 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × nilotinib × Clear all
NCT05564377 2026-05-27

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05554341 2026-05-14

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02029001 2025-08-07

MOST plus

Centre Leon Berard

Phase 2 Recruiting
900 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01089595 2017-03-15

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Fox Chase Cancer Center

Phase 2 Terminated
5 enrolled 8 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡